Image source: Pixabay

Highlights

  • Amphastar exceeded industry benchmarks in FY23, showcasing impressive margins and a superior return on equity.
  • The company’s net revenue and net income surged by 29.1% and 50.5%, respectively, in FY23 compared to FY22.
  • With a positive outlook, the company anticipates continued growth driven by advancements in its pipeline product candidates.

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a biopharmaceutical company with a major focus on developing, manufacturing, marketing, and selling technically-challenging inhalation, generic and injectable, and intranasal products. Additionally, it sells insulin API products.

In the fiscal year 2023, Amphastar exceeded industry benchmarks across a range of financial measures, indicating its robust operational efficiency and profitability. The company showcased strong margins compared to industry norms, with an EBITDA margin of 36.9% versus the industry median of 22.2%; an operating margin of 30.1% compared to the industry's average of 7.5%; a pretax margin of 26.6% versus the industry's0.2%, and a net margin of 21.7% compared to the industry's -0.1%. Furthermore, AMPH demonstrated a superior return on equity (ROE) of 23.6%, significantly outperforming the industry median of -5.4%, underscoring its efficient use of shareholder equity to generate profits and enhance shareholder value.

Further, the company’s net revenue and net income surged by 29.1% and 50.5%, respectively in FY23 compared to FY22.

Recent business update

The company will release the results of its first quarter of 2024 (period ended March 31, 2024) after the market closes on 08 May 2024.

Company outlook

The company holds an optimistic outlook for the upcoming year, foreseeing the advancement of its numerous pipeline product candidates through various stages of development.

Top 10 shareholders

The combined holdings of the top 10 shareholders amount to approximately 56.27% of the total shares, indicating a diverse shareholding. Applied Physics & Chemistry Laboratories, Inc., and BlackRock Institutional Trust Company, N.A. stand out as the largest shareholders, commanding the highest stakes in the company with approximately 13.97% and 11.42% ownership, respectively.

Stock Performance:

The share price of AMPH has plummeted by around  21.14% and 31.79%  in the past three months and past nine months, respectively. The stock is currently trading near the lower band of its 52-week high and low range of USD 67.66-35.93.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is May 01, 2024. The reference data in this report has been partly sourced from EODHD/Others.